Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

RLIP76 Inhibition: A Promising Developmental Therapy for Neuroblastoma.

Pharmaceutical research - 1 Aug 2017

Singhal Sharad S, Nagaprashantha Lokesh, Singhal Preeti, Singhal Sulabh, Singhal Jyotsana, Awasthi Sanjay, Horne David

Abstract excerpt

Refractory and relapsed neuroblastoma (NB) present with significant challenges in clinical management. Though primary NBs largely with wild-type p53 respond well to interventions, dysfunctional signaling in the p53 pathways in a MYCN oncogene driven background is found in a number of children with NB. The p53-mutant NB is largely unresponsive to available therapies and p53-independent targeted therapeutics...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibodies
Share to Clathrin
Share to Endocytosis

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Glutathione

Share to GTPase-Activating Proteins

Share to Molecular Targeted Therapy

Share to Neoplasm Recurrence, Local

Share to Neuroblastoma

Source

Identifiers

PMID: 28386633
DOI: 10.1007/s11095-017-2154-y

Genes

MYCN

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

RLIP76 Inhibition: A Promising Developmental Therapy for Neuroblastoma.PMID 28386633Read ↗

Revolutionizing pediatric neuroblastoma treatment: unraveling new molecular targets for precision interventionsSemantic proximity Read ↗

Didymin: an orally active citrus flavonoid for targeting neuroblastomaSemantic proximity Read ↗

Subcellular Distribution of p53 by the p53-Responsive lncRNA NBAT1 Determines Chemotherapeutic Response in NeuroblastomaSemantic proximity Read ↗

Neuroblastoma: An Updated Review on Biology and TreatmentSemantic proximity Read ↗

Combined targeting of PRDX6 and GSTP1 as a potential differentiation strategy for neuroblastoma treatmentSemantic proximity Read ↗

Therapy resistance in neuroblastoma: Mechanisms and reversal strategiesSemantic proximity Read ↗

A kinome-wide RNAi screen identifies ALK as a target to sensitize neuroblastoma cells for HDAC8-inhibitor treatmentSemantic proximity Read ↗

MYCN mediates TFRC-dependent ferroptosis and reveals vulnerabilities in neuroblastomaSemantic proximity Read ↗

Combining selinexor with alisertib to target the p53 pathway in neuroblastomaSemantic proximity Read ↗

Retinoic acid and TGF-β signalling cooperate to overcome MYCN-induced retinoid resistanceSemantic proximity Read ↗

Zebrafish as a Neuroblastoma Model: Progress Made, Promise for the Future.Semantic proximity Read ↗

TRIM59-mediated ferroptosis enhances neuroblastoma development and chemosensitivity through p53 ubiquitination and degradationSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.